ATE329621T1 - Pharmazeutische injizierbare lösungen, die paracetamol und kombinationen aus paracetamol mit anderen aktivsubstanzen enthalten - Google Patents

Pharmazeutische injizierbare lösungen, die paracetamol und kombinationen aus paracetamol mit anderen aktivsubstanzen enthalten

Info

Publication number
ATE329621T1
ATE329621T1 AT02023125T AT02023125T ATE329621T1 AT E329621 T1 ATE329621 T1 AT E329621T1 AT 02023125 T AT02023125 T AT 02023125T AT 02023125 T AT02023125 T AT 02023125T AT E329621 T1 ATE329621 T1 AT E329621T1
Authority
AT
Austria
Prior art keywords
paracetamol
combinations
active substances
injectable solutions
solutions containing
Prior art date
Application number
AT02023125T
Other languages
English (en)
Inventor
Julia Tsetis
Original Assignee
Uni Pharma Kleon Tsetis Pharmaceutical Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8230107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE329621(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uni Pharma Kleon Tsetis Pharmaceutical Lab Sa filed Critical Uni Pharma Kleon Tsetis Pharmaceutical Lab Sa
Application granted granted Critical
Publication of ATE329621T1 publication Critical patent/ATE329621T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02023125T 1997-11-18 1997-11-18 Pharmazeutische injizierbare lösungen, die paracetamol und kombinationen aus paracetamol mit anderen aktivsubstanzen enthalten ATE329621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02023125A EP1285667B1 (de) 1997-11-18 1997-11-18 Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
EP97600009A EP0916347B1 (de) 1997-11-18 1997-11-18 Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten

Publications (1)

Publication Number Publication Date
ATE329621T1 true ATE329621T1 (de) 2006-07-15

Family

ID=8230107

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97600009T ATE232741T1 (de) 1997-11-18 1997-11-18 Pharmazeutische injizierbare lösungen, die paracetamol und kombinationen aus paracetamol mit anderen aktivsubstanzen enthalten
AT02023125T ATE329621T1 (de) 1997-11-18 1997-11-18 Pharmazeutische injizierbare lösungen, die paracetamol und kombinationen aus paracetamol mit anderen aktivsubstanzen enthalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97600009T ATE232741T1 (de) 1997-11-18 1997-11-18 Pharmazeutische injizierbare lösungen, die paracetamol und kombinationen aus paracetamol mit anderen aktivsubstanzen enthalten

Country Status (9)

Country Link
EP (2) EP0916347B1 (de)
AT (2) ATE232741T1 (de)
CY (1) CY2562B1 (de)
DE (2) DE69719189T2 (de)
DK (2) DK1285667T3 (de)
ES (2) ES2192256T3 (de)
HK (1) HK1020866A1 (de)
PT (2) PT1285667E (de)
SI (2) SI1285667T1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1003969B (el) * 2001-02-05 2002-08-14 U��-Pharma ����� ������ ������������ ���������� ���� Σταθερα φαρμακευτικα διαλυματα νιμεσουλιδης.
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
EP1469885A1 (de) * 2001-12-18 2004-10-27 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Parenterale paracetamol-zusammensetzung
FR2851164B1 (fr) * 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
AU2006346318B2 (en) * 2006-07-18 2011-02-10 Genfarma Laboratorio S.L. Injectable liquid paracetamol formulation
EP2307056B1 (de) * 2008-01-17 2021-12-15 Pharmis Biofarmacêutica, LDA Stabilisierte wässrige formulierung mit paracetamol
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
US8404748B2 (en) 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
EP2464332B1 (de) 2009-08-13 2016-03-02 Neogen N.V. Lagerstabile formulierung von paracetamol in einer wässrigen lösung
CA2802303C (en) 2010-06-30 2016-06-14 Troikaa Pharmaceuticals Limited Pharmaceutical compositions comprising paracetamol and process for preparing the same
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US9089477B2 (en) 2011-02-10 2015-07-28 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
EA028572B1 (ru) 2011-03-10 2017-12-29 Ксерис Фармасьютикалс, Инк. Стабильная композиция для парентеральной инъекции и способы ее получения и использования
AU2012332556B2 (en) 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
JP6982495B2 (ja) 2014-08-06 2021-12-17 ゼリス ファーマシューティカルズ インコーポレイテッド ペーストの皮内および/または皮下注射のためのシリンジ、キット、および方法
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP4378463A2 (de) 2017-06-02 2024-06-05 Xeris Pharmaceuticals, Inc. Niederschlagsbeständige kleinmolekulare zubereitung
GB201811858D0 (en) * 2018-07-20 2018-09-05 Wockhardt Uk Ltd Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3111591A1 (de) * 1981-03-24 1982-10-14 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Blutdrucksenkendes arzneimittel
US5296241A (en) * 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
GR1001523B (el) * 1991-07-04 1994-01-28 Uni Pharma Tsetis Kleon Farmak Ενέσιμα διαλύματα του συνδυασμού παρακεταμόλης και κωδεϊνης.
NZ248486A (en) * 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
GR1002731B (el) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.

Also Published As

Publication number Publication date
EP1285667B1 (de) 2006-06-14
DK1285667T3 (da) 2006-09-11
EP1285667A3 (de) 2003-03-26
EP0916347A1 (de) 1999-05-19
SI0916347T1 (en) 2003-06-30
PT1285667E (pt) 2006-11-30
EP1285667A2 (de) 2003-02-26
DK0916347T3 (da) 2003-04-22
HK1020866A1 (en) 2000-05-26
ATE232741T1 (de) 2003-03-15
SI1285667T1 (sl) 2006-10-31
CY2562B1 (en) 2008-07-02
DE69736140T2 (de) 2007-04-19
EP0916347B1 (de) 2003-02-19
ES2265470T3 (es) 2007-02-16
DE69719189D1 (de) 2003-03-27
DE69719189T2 (de) 2003-11-27
ES2192256T3 (es) 2003-10-01
DE69736140D1 (de) 2006-07-27
PT916347E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
CY2562B1 (en) Pharmaceutical injectable solution of paracetamol and combinations of paracetamol with other active substances
NO960948L (no) Farmasöytisk flerenhetspreparat inneholdende protonpumpeinhibitor
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ATE334689T1 (de) Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
ATE64297T1 (de) Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung.
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
DE69123795D1 (de) Pharmazeutische Zusammensetzung zur rektalen Verabreichung von Wirkstoffen mit topischer medizinischer Wirkung im Dickdarmniveau
ATE401869T1 (de) Pharmazeutische zubereitungen zur externen anwendung, die nicht steroidale antiinflammatorische und analgetische wirkstoffe enthalten
ATE529097T1 (de) Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
ITMI913170A1 (it) Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
ES2109131B1 (es) Composicion farmaceutica que tiene actividad analgesica.
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
KR910014337A (ko) d-2-(6-메톡시-2-나프릴)-프로피온산의 광학활성 유도체와 이것을 함유한 약제학적 조성물
CO4370014A1 (es) Soluciones inyectables estables de diritromicina
JPS5762220A (en) Embrocation for external use
DE69716485D1 (de) Taxol enthaltende pharmazeutische injektionslösung
ES2146683T3 (es) Uso de bifemelano para la fabricacion de un medicamento para el tratamiento de trastornos hipercineticos.
KR927003530A (ko) 이온삼투요법용 제약 제제의 제조에 있어서의 국소 마취제의 용도
SE8304818D0 (sv) A medicine having anti-ulcer, spasmolytic and locally anesthetic effect
ES2043093T3 (es) Composicion para uso cosmetico o farmaceutico.
ATE90560T1 (de) Verwendung einer hydroxyoctadecadiensaeure, deren zur ketoform oxidierte saeure sowie deren derivate zur therapie oestrogenabhaengiger krankheiten, sowie pharmazeutische zusammensetzungen, die diese enthalten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1285667

Country of ref document: EP